Jean Michel Pawlotsky

Summary

Country: France

Publications

  1. doi request reprint Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes
    Stephane Chevaliez
    Department of Virology and INSERM U955, French National Reference Centre for Viral Hepatitis B, C and delta, Hopital Henri Mondor, Universite Paris, Creteil, France
    Best Pract Res Clin Gastroenterol 22:1031-48. 2008
  2. ncbi request reprint Use and interpretation of virological tests for hepatitis C
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Hepatology 36:S65-73. 2002
  3. pmc Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay
    Karine Gourlain
    Department of Virology, INSERM U635, Creteil, France
    J Clin Microbiol 43:1669-73. 2005
  4. pmc Analysis of ribavirin mutagenicity in human hepatitis C virus infection
    Stephane Chevaliez
    Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    J Virol 81:7732-41. 2007
  5. ncbi request reprint Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication
    Magali Bouvier-Alias
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Hepatology 36:211-8. 2002
  6. ncbi request reprint Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    J Hepatol 46:791-6. 2007
  7. ncbi request reprint Antiviral action of ribavirin in chronic hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Gastroenterology 126:703-14. 2004
  8. pmc New virologic tools for management of chronic hepatitis B and C
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C, and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Gastroenterology 142:1303-1313.e1. 2012
  9. pmc Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    PLoS ONE 4:e8209. 2009
  10. ncbi request reprint Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resist
    Muriel Soler
    Departament of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Antivir Ther 9:953-68. 2004

Collaborators

Detail Information

Publications92

  1. doi request reprint Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes
    Stephane Chevaliez
    Department of Virology and INSERM U955, French National Reference Centre for Viral Hepatitis B, C and delta, Hopital Henri Mondor, Universite Paris, Creteil, France
    Best Pract Res Clin Gastroenterol 22:1031-48. 2008
    ..The HCV genotype and on-treatment viral kinetics can be used to tailor treatment dosages and duration...
  2. ncbi request reprint Use and interpretation of virological tests for hepatitis C
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Hepatology 36:S65-73. 2002
    ..This article reviews the kinetics of HCV markers during acute and chronic HCV infection, together with current assays and their practical use in the management of HCV-infected patients...
  3. pmc Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay
    Karine Gourlain
    Department of Virology, INSERM U635, Creteil, France
    J Clin Microbiol 43:1669-73. 2005
    ..These results emphasize the need for commercial HCV RNA quantification assays with a broader range of linear quantification, such as real-time PCR-based assays...
  4. pmc Analysis of ribavirin mutagenicity in human hepatitis C virus infection
    Stephane Chevaliez
    Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    J Virol 81:7732-41. 2007
    ..This study strongly undermines the hypothesis whereby ribavirin acts as an HCV mutagen in vivo...
  5. ncbi request reprint Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication
    Magali Bouvier-Alias
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Hepatology 36:211-8. 2002
    ..Nevertheless, the total HCV core Ag assay cannot be used as a marker of viral replication for HCV RNA values below 20,000 IU/mL, limiting its use in the monitoring of late events during and after antiviral treatment...
  6. ncbi request reprint Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    J Hepatol 46:791-6. 2007
    ..Some patients receiving adefovir at the approved dose of 10 mg daily for chronic hepatitis B have a "suboptimal" virological response characterized by a slow and moderate decrease in viral replication...
  7. ncbi request reprint Antiviral action of ribavirin in chronic hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Gastroenterology 126:703-14. 2004
    ..Our aim was to assess the antiviral action of ribavirin on hepatitis C virus (HCV) as a function of ribavirin pharmacokinetics and to evaluate the influence of this antiviral effect on IFN-alpha efficacy...
  8. pmc New virologic tools for management of chronic hepatitis B and C
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C, and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Gastroenterology 142:1303-1313.e1. 2012
    ..We review these new virologic methods and their clinical and research applications to HBV and HCV infections...
  9. pmc Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    PLoS ONE 4:e8209. 2009
    ..The goal of this study was to identify the appropriate molecular tool(s) for accurate HCV genotype 1 subtype determination...
  10. ncbi request reprint Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resist
    Muriel Soler
    Departament of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Antivir Ther 9:953-68. 2004
    ..Furthermore, no obvious nucleotide changes in the surrounding IRES region that might possibly affect oligonucleotide binding were detected...
  11. ncbi request reprint Treating hepatitis C in "difficult-to-treat" patients
    Jean Michel Pawlotsky
    Department of Virology, INSERM Unité 635, Henri Mondor Hospital, University of Paris XII, Creteil, France
    N Engl J Med 351:422-3. 2004
  12. ncbi request reprint Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS
    Dominique Challine
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Med Virol 67:510-5. 2002
    ..These results argue against an in vivo interaction between HCV and EBV in patients with AIDS, and against a role of HCV infection in the occurrence of B-cell non-Hodgkin's lymphoma in these patients...
  13. doi request reprint Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase
    Abdelhakim Ahmed-Belkacem
    Research Team Pathophysiology and Therapy of Chronic Viral Hepatitis, INSERM U955, Creteil, France
    Gastroenterology 138:1112-22. 2010
    ..The aim of this study was to test the principal isomers contained in silymarin preparations for their ability to inhibit HCV enzymatic functions and replication in different models...
  14. doi request reprint High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial)
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, INSERM U955, Creteil, France
    Gastroenterology 141:119-27. 2011
    ..The influence of genetic determinants in this context remains unknown...
  15. doi request reprint Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    J Hepatol 58:676-83. 2013
    ..The aim of the present study was to assess whether finite nucleoside/nucleotide analogue treatment duration could be envisaged during the patient's lifetime...
  16. ncbi request reprint Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Creteil, France
    Hepatology 46:22-31. 2007
    ....
  17. ncbi request reprint Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics
    Jean Michel Pawlotsky
    Department of Virology, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Semin Liver Dis 23:3-11. 2003
    ..These approaches will be particularly useful in studying the mechanisms of HCV treatment failure with new HCV inhibitors currently under development...
  18. ncbi request reprint Serological viral testing of cadaveric cornea donors
    Dominique Challine
    Viral Emergency and Organ, Tissue, and Cell Donor Screening Laboratory, Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Transplantation 82:788-93. 2006
    ..Cadaveric donor serum is often of poor quality and frequently yields falsely positive results in serological assays that may result in the graft being needlessly discarded...
  19. doi request reprint Hepatitis C virus (HCV) protein expression enhances hepatic fibrosis in HCV transgenic mice exposed to a fibrogenic agent
    Philippe Chouteau
    INSERM U955, Creteil, France Université Paris Est, Creteil, France
    J Hepatol 57:499-507. 2012
    ..During chronic HCV infection, activation of fibrogenesis appears to be principally related to local inflammation. However, the direct role of hepatic HCV protein expression in fibrogenesis remains unknown...
  20. pmc Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    J Clin Microbiol 48:3641-7. 2010
    ..Overall, the CAP/CTM assay, version 2.0, is well suited to monitoring clinical HBV DNA levels according to current clinical practice guidelines...
  21. doi request reprint Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    ..Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...
  22. ncbi request reprint Use of virologic assays in the diagnosis and management of hepatitis C virus infection
    Stephane Chevaliez
    Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Clin Liver Dis 9:371-82, v. 2005
    ..The continuing development of test systems accompanied by new antiviral drugs and novel therapeutic approaches should lead to an optimization of the treatment of HCV infection...
  23. ncbi request reprint Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    Hepatology 42:63-71. 2005
    ..In conclusion, daily cannabis smoking is significantly associated with fibrosis progression during CHC. Patients with ongoing CHC should be advised to refrain from regular cannabis use...
  24. doi request reprint Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors
    Dominique Challine
    Department of Virology, French National Reference Center for Viral Hepatitis B, C and delta, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Gastroenterology 135:1185-91. 2008
    ..This study assessed the risk of HBV associated with different HBV serologic profiles in organ, tissue, and cell transplants, as well as the risk of HBV transmission from seronegative donors...
  25. ncbi request reprint Hepatitis C virus genetic variability: pathogenic and clinical implications
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, Creteil 94010, France
    Clin Liver Dis 7:45-66. 2003
    ..Further studies are needed to understand better the implications of HCV quasispecies diversity in the pathophysiology of HCV infection...
  26. ncbi request reprint Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy
    Muriel Soler
    Department of Virology EA 3489, Universite Paris XII, Creteil, France
    Virology 298:160-73. 2002
    ..In contrast, the overall quasispecies distribution of HCV genomes (including IRES sequences) might participate in regulation of hepatic and extrahepatic HCV replication...
  27. ncbi request reprint Molecular diagnosis of viral hepatitis
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Gastroenterology 122:1554-68. 2002
    ..This article reviews current molecular biology-based techniques and assays, and their practical use in the management of hepatitis B and C virus infection...
  28. ncbi request reprint HIV and hepatitis C virus RNA in seronegative organ and tissue donors
    Dominique Challine
    Viral Emergency and Organ, Tissue, and Cell Donor Screening Laboratory, Department of Virology INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Lancet 364:1611-2. 2004
    ..No HIV-seronegative, HIV RNA-positive donor was identified. Our data suggest that routine nucleic acid testing of organ and tissue donors might increase viral safety in transplantation...
  29. pmc The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    J Clin Microbiol 51:1078-82. 2013
    ..In conclusion, CAP/CTM HCV v2.0 accurately quantifies HCV RNA in genotype 4 clinical specimens, regardless of the subtype, and can be confidently used in clinical trials and clinical practice with this genotype...
  30. ncbi request reprint Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    J Hepatol 39:S31-5. 2003
  31. ncbi request reprint The hepatitis C virus life cycle as a target for new antiviral therapies
    Jean Michel Pawlotsky
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Gastroenterology 132:1979-98. 2007
    ....
  32. ncbi request reprint Therapy of hepatitis C: from empiricism to eradication
    Jean Michel Pawlotsky
    Hopital Henri Mondor, Creteil, France
    Hepatology 43:S207-20. 2006
    ..New treatments and vaccines might make it possible to eradicate HCV in the future...
  33. ncbi request reprint Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users
    Yoann Morice
    Department of Virology and INSERM U635, French National Reference Center for Viral Hepatitis B, C and delta, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    J Med Virol 78:1296-303. 2006
    ..Regional transmission occurred in the recent past, leading to an embryonic genetic diversification of HCV-3a among local injecting drug user population...
  34. ncbi request reprint Future therapies for hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris, Creteil, France
    Antivir Ther 11:397-408. 2006
    ....
  35. doi request reprint The science of direct-acting antiviral and host-targeted agent therapy
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Antivir Ther 17:1109-17. 2012
    ..Further results are awaited that will allow the establishment of an ideal first-line all-oral, interferon-free treatment regimen for patients with chronic HCV infection...
  36. doi request reprint Virology of hepatitis C virus infection
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Best Pract Res Clin Gastroenterol 26:381-9. 2012
    ..Virological tools are used in clinical practice to diagnose acute and chronic HCV infection, to decide who should be treated, to select the optimal therapy and to monitor treatment responses in order to tailor treatment duration...
  37. pmc Seroconversion to hepatitis C virus alternate reading frame protein during acute infection
    Yoann Morice
    National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Henri Mondor Hospital, University of Paris 12, Creteil, France
    Hepatology 49:1449-59. 2009
    ..However, seroconversion does not occur in all patients for unknown reasons. Alternate reading frame protein could be generated by minority quasispecies variants or variants that occur transiently...
  38. ncbi request reprint Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Hepatology 39:554-67. 2004
  39. ncbi request reprint Use and interpretation of hepatitis C virus diagnostic assays
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, Creteil 94010, France
    Clin Liver Dis 7:127-37. 2003
    ..These improvements, and the development of new antiviral drugs (see the article by Drs. DeFrancesco and Rice elsewhere in this issue), should help to optimize the treatment of HCV infection...
  40. pmc Regulation of hepatitis C virus replication by nuclear translocation of nonstructural 5A protein and transcriptional activation of host genes
    Muhammad Ahmad Maqbool
    Institut National de la Santé et de la Recherche Médicale U955, Universite Paris Est, Creteil, France
    J Virol 87:5523-39. 2013
    ..Taken together, these results demonstrate a new mechanism by which HCV modulates its cellular environment, thereby enhancing viral replication...
  41. doi request reprint Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Jean Michel Pawlotsky
    Department of Virology, Hopital Henri Mondor, Universite Paris Est, 51 Avenue du Marechal de Lattre de Tassigny, 94010, Creteil, France
    Curr Gastroenterol Rep 15:309. 2013
    ..Whether response-guided therapy will still be useful in the era of all-oral, interferon-free regimens remains uncertain...
  42. pmc Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest
    Martin R Higgs
    Institut National de la Santé et de la Recherche Médicale U955, Creteil, France
    Cancer Res 70:4901-11. 2010
    ....
  43. doi request reprint Animal models in the study of hepatitis C virus-associated liver pathologies
    Herve Lerat
    Institut National de la Sante et de la Recherche Medicale, Unite U955, Universite Paris Est, Creteil, F 94010, France
    Expert Rev Gastroenterol Hepatol 5:341-52. 2011
    ..Then, we will provide an overview of how these models have contributed to the deciphering of the molecular mechanisms underlying dysregulated lipid metabolism and hepatocellular carcinoma during HCV infection...
  44. ncbi request reprint Pathophysiology of hepatitis C virus infection and related liver disease
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Trends Microbiol 12:96-102. 2004
    ..The role of HCV proteins in hepatocarcinogenesis is unknown. Further progress in our understanding of HCV infection and pathogenesis awaits the advent of new model systems and technologies...
  45. ncbi request reprint The nature of interferon-alpha resistance in hepatitis C virus infection
    Jean Michel Pawlotsky
    Department of Virology, Henri Mondor Hospital, Paris XII University, Creteil, France
    Curr Opin Infect Dis 16:587-92. 2003
    ..IFN resistance could also play a role in the virological response to IFN therapy through similar or different mechanisms. The involved mechanisms however remain unclear...
  46. pmc Complex dynamics of hepatitis B virus resistance to adefovir
    Coralie Pallier
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Hepatology 49:50-9. 2009
    ..Whether these adefovir resistance-associated substitutions may confer cross-resistance to tenofovir in vivo will need to be determined...
  47. ncbi request reprint Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010, Creteil, France
    Antiviral Res 59:1-11. 2003
    ..This article discusses current knowledge of the mechanisms of action of IFN-alpha and ribavirin, the virological characteristics of chronic hepatitis C treatment success and failure, and possible underlying mechanisms...
  48. ncbi request reprint Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C
    Owonayo Oniankitan
    Department of Rheumatology, Henri Mondor Teaching Hospital, AP HP, Creteil, France
    J Rheumatol 31:107-9. 2004
    ..To describe the safety of tumor necrosis factor-a blockade in 2 patients with inflammatory rheumatic disease with chronic hepatitis B and C...
  49. ncbi request reprint Interferon-based therapy of hepatitis C
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Adv Drug Deliv Rev 59:1222-41. 2007
    ..Finally, insights into new hepatitis C drug developments are given...
  50. doi request reprint Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Antivir Ther 17:411-23. 2012
    ....
  51. doi request reprint How to use virological tools for optimal management of chronic hepatitis C
    Stephane Chevaliez
    Department of Virology and INSERM U841, French National Reference Center for Viral Hepatitis B, C and delta, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Liver Int 29:9-14. 2009
    ..Thus, virological assays are indispensable in the diagnosis and management of individuals infected with the HCV...
  52. pmc Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach
    Jean Michel Pawlotsky
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Gastroenterology 134:405-15. 2008
    ..This article discusses HBV virologic markers and tests, and their optimal use both for planning and reporting clinical trials and in clinical practice...
  53. doi request reprint Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing
    Christophe Rodriguez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Hepatology 58:890-901. 2013
    ..The UDPS-based approach described here is likely to have important implications for the assessment of antiviral drug resistance in research and clinical practice...
  54. doi request reprint Treatment of chronic hepatitis C: current and future
    Jean Michel Pawlotsky
    Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Curr Top Microbiol Immunol 369:321-42. 2013
    ..This chapter provides an overview of the current treatment of HCV infection and discusses the future of HCV therapy with new anti-HCV drugs...
  55. doi request reprint Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, AP HP, Universite Paris Est, INSERM U955, Creteil, France
    J Hepatol 59:434-41. 2013
    ..We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme...
  56. doi request reprint Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit
    Emmanuelle Girou
    Infection Control Unit, Henri Mondor Hospital, Creteil, France
    Clin Infect Dis 47:627-33. 2008
    ..A prospective observational study was conducted to assess the roles of environmental contamination and noncompliance with standard precautions in HCV cross-transmission in a hemodialysis unit...
  57. ncbi request reprint [Management of patients with hepatitis C virus infection. Virological tests]
    Jean Michel Pawlotsky
    Laboratoire de Virologie EA 3489, Hopital Henri Mondor, Universite Paris XII, Creteil
    Gastroenterol Clin Biol 26:B180-7. 2002
  58. pmc An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies
    Birke Bartosch
    Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, INSERM U412, Ecole Normale Superieure de Lyon, IFR128 Biosciences Lyon Gerland, Lyon, France
    J Virol 79:8217-29. 2005
    ..By preserving a balance between these functions, HVR1 may be essential for the viral persistence of HCV...
  59. ncbi request reprint [Screening and diagnosis of hepatitis B and C]
    Stephane Chevaliez
    Laboratoire de Virologie, INSERM U635, Hopital Henri Mondor, Universite Paris 12, 94010 Creteil Cedex
    Rev Prat 55:615-23. 2005
    ..HCV genotype determination is used to tailor the treatment schedule to the individual patient. Treatment efficacy is assessed by means of molecular techniques to prove progressive and definitive viral clearance...
  60. pmc Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection
    Dimitri Lavillette
    LVRTG, ENS de Lyon, 46 allee d Italie, 69364 Lyon Cedex 07, France
    J Virol 79:6023-34. 2005
    ..These results provide new insights into the mechanisms of viral persistence and immune control of viremia...
  61. ncbi request reprint Current and future concepts in hepatitis C therapy
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Creteil, France
    Semin Liver Dis 25:72-83. 2005
    ..Drug combinations will be tailored to the individual patient, based on baseline parameters and viral kinetics during therapy...
  62. pmc Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study
    Syria Laperche
    Centre National de Référence pour les Hépatites B et C en Transfusion, Département des Agents Transmissible par le Sang, Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015 Paris, France
    J Clin Microbiol 43:733-9. 2005
    ....
  63. ncbi request reprint Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    J Hepatol 41:935-42. 2004
    ....
  64. ncbi request reprint Management of antiviral resistance in patients with chronic hepatitis B
    Stephen Locarnini
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia
    Antivir Ther 9:679-93. 2004
    ..Potential strategies to prevent the emergence of resistance and how to manage drug-resistant HBV once it emerges are discussed...
  65. ncbi request reprint Immunological and virological effects of ribavirin in hepatitis C after liver transplantation
    Rafael Quadri
    Division of Gastroenterology and Hepatology, University Hospital, 1211 Geneva, Switzerland
    Transplantation 73:373-8. 2002
    ..A better understanding of the mechanisms of action of drugs currently used to manage hepatitis C would be helpful...
  66. pmc Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study
    Syria Laperche
    Centre National de Référence pour les Hépatites B et C en Transfusion, Département des Agents Transmissibles par le Sang, Institut National de la Transfusion Sanguine, Paris, France
    J Clin Microbiol 44:3600-7. 2006
    ..Furthermore, the clinical implications of HBV genotyping and the determination of precore/core mutants need to be clearly stated to justify the standardization of these methods...
  67. pmc Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro
    Valerie Castet
    INSERM U128, Montpellier, France
    J Virol 76:8189-99. 2002
    ..These results show that IFN-alpha acts primarily through its nonspecific antiviral effects and suggest that primary cultures of human hepatocytes may provide a good model to study intrinsic HCV resistance to IFN-alpha...
  68. ncbi request reprint Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis
    Christophe Duvoux
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, Universite Paris XII, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Transpl Int 15:3-9. 2002
    ..Cryoglobulinemia did not seem to be associated with more severe graft damage. Cryoglobulinemia-associated morbidity must be taken into account in the management of post-transplant HCV infection...
  69. pmc Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum
    Jean Jacques Lefrere
    centre hospitalo universitaire d Amiens, France
    J Clin Microbiol 42:2027-30. 2004
    ....
  70. pmc Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions
    Muriel Pellerin
    Department of Virology INSERM U635, Hopital Henri Mondor, Universite Paris XII, 94010 Creteil, France
    J Virol 78:4617-27. 2004
    ..This feature of quasispecies-distributed viruses could play an important role in various aspects of the viral life cycle and related disease...
  71. ncbi request reprint [Steasis and hepatitis C]
    Christophe Hezode
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil
    Gastroenterol Clin Biol 27:1091-5. 2003
  72. ncbi request reprint Hepatitis C: it's a long way to new therapy, it's a long way to go
    Jean Michel Pawlotsky
    Gastroenterology 127:1629-32. 2004
  73. ncbi request reprint International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
    ..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response...
  74. ncbi request reprint Virology of hepatitis B and C viruses and antiviral targets
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris 12, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    J Hepatol 44:S10-3. 2006
    ..The issue of cccDNA clearance, however, remains in hepatitis B treatment, whereas HCV infection is curable...
  75. ncbi request reprint Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6
    Esther Lukasiewicz
    Hepatology 45:258-9. 2007
  76. ncbi request reprint [New therapeutic strategies in chronic hepatitis C]
    Jean Michel Pawlotsky
    Gastroenterol Clin Biol 30:1009-11. 2006
  77. ncbi request reprint Treatment of hepatitis C: don't put all your eggs in one basket!
    Jean Michel Pawlotsky
    Gastroenterology 132:1611-5. 2007
  78. ncbi request reprint Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C
    Johan Westin
    Hepatology 45:1333-4; author reply 1334. 2007
  79. ncbi request reprint Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
    Jean Pierre Bronowicki
    Department of Hepatology and Gastroenterology, INSERM U724, CHU de Nancy, Vandoeuvre les Nancy, France
    Gastroenterology 131:1040-8. 2006
    ..We aimed to investigate the role of ribavirin in HCV clearance during therapy and to evaluate the consequences of ribavirin discontinuation in patients infected with genotype 1 hepatitis C who cleared HCV RNA at week 24...
  80. ncbi request reprint Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
    ..We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4...
  81. ncbi request reprint Hepatitis C virus: virology, diagnosis and management of antiviral therapy
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U 841, Hopital Henri Mondor, 94010 Creteil, France
    World J Gastroenterol 13:2461-6. 2007
    ..e. the endpoint of therapy...
  82. ncbi request reprint Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
    Anna S Lok
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 46:254-65. 2007
    ..Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy...
  83. pmc Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C
    Laurent Castera
    Department of Hepatology and Gastroenterology, C H U Bordeaux, Hopital Haut Leveque, Pessac, France
    MedGenMed 7:39. 2005
  84. ncbi request reprint HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
    Massimo Pilli
    Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Gastroenterology 133:1132-43. 2007
    ....
  85. ncbi request reprint [HCV non-responder patients: definition of non-response and treatment strategy]
    Patrick Marcellin
    Service d Hepatologie, INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 31:4S13-9. 2007
    ..The drugs, currently in phase 1 and 2, which will demonstrate their efficacy and safety, should not be available before several years...
  86. doi request reprint Chronic hepatitis B: preventing, detecting, and managing viral resistance
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Gastroenterol Hepatol 6:268-74. 2008
    ..Despite the substantial advances in treatment made to date, new agents with novel viral targets will be needed for patients who ultimately may fail second- or third-line therapy...
  87. doi request reprint Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy
    Paolo Pugnale
    Department of Pathology and Immunology, University of Geneva Medical Center, 1211 Geneva, Switzerland
    J Hepatol 48:932-8. 2008
    ..Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response...
  88. doi request reprint Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis
    Aurélie Piodi
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, France
    Hepatology 48:16-27. 2008
    ..Importantly, we found no genetic or functional differences between genotype 3a core proteins from patients with and without HCV-induced steatosis...
  89. pmc Unique NS5b hepatitis C virus gene sequence consensus database is essential for standardization of genotype determinations in multicenter epidemiological studies
    Syria Laperche
    Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015 Paris, France
    J Clin Microbiol 44:614-6. 2006
    ....
  90. ncbi request reprint A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 43:73-80. 2008
    ....
  91. ncbi request reprint The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice
    John G McHutchison
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Centre, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27707, USA
    J Hepatol 44:411-21. 2006
  92. ncbi request reprint IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...